Perspectives
Perspectives: Dr. Carlos Schenck discusses REM-sleep behavior disorder
May. 19, 2022
This is an image preview.
Start a Free Account
to view the full image.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Schematic representation of neurotransmitters and receptor subtypes involved in yawning
Important neural pathways involved in the regulation of yawning include: (1) two groups of oxytocinergic neurons projecting from the paraventricular nucleus of the hypothalamus (PVN) to the CA1 region of the hippocampus, or the pons, medulla or spinal cord; (2) ACTH-/α-MSH-activated neurons projecting from the PVN to the hippocampus by activation of cholinergic septo-hippocampal neurons; (3) direct activation of cholinergic septo-hippocampal/hippocampal neurons; and (4) a serotonergic-cholinergic pathway. Neurotransmitter systems and receptors that stimulate or enhance yawning are denoted by a plus sign, whereas those that inhibit yawning are denoted by a minus sign. Abbreviations: ACh - acetylcholine; ACTH - adrenocorticotrophic hormone; Adr - adrenergic; GABA - gamma amino butyric acid; 5-HT - serontonin; MSH - alpha-melanocyte-stimulating hormone; NMDA - N-methyl-D-aspartate; NO - nitric oxide; OTXR - oxytocin receptor; PVN - paraventricular nucleus of the hypothalamus. (Source: Teive HA, Munhoz RP, Camargo CHF, Walusinski O. Yawning in neurology: a review. Arq Neuropsiquiatr 2018;76(7):473-80. Creative Commons Attribution [CC BY] License. The original source of the image and the source explanation for the components illustrated was from: Collins GT, Eguibar JR. Neuropharmacology of yawning. Front Neurol Neurosci 2010;28:90-106.)